Neurosense Therapeutics (NRSN) Reports Positive Biomarker Data from ALS Phase 2b Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/21/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. BJ
9. OSIS
10. FMG:AU

Go back to Neurosense Therapeutics (NRSN) Reports Positive Biomarker Data from ALS Phase 2b Clinical Trial
(NASDAQ: NRSN) Delayed: 0.37 +0.02 (5.71%)
Previous Close $0.35    52 Week High $ 
Open $0.36    52 Week Low $ 
Day High $0.39    P/E N/A 
Day Low $0.35    EPS $ 
Volume 61,906